Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer.
Original Article: Bristol-Myers to get negative CHMP opinion on renal cancer drugs